Faruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against PharMerica Corporation
Summary
1:17-cv-01301, on behalf of shareholders of PharMerica Corporation ("PharMerica" or the "Company") (NYSE: PMC) who have been harmed by PharMericas and its board of directors (the "Board") alleged violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the proposed merger of the Company with affiliates of Kohlberg Kravis Roberts & Co. L.P. ("KKR"). The complaint alleges that the Preliminary Proxy Statement on a Schedule 14A (the "Proxy") filed with the Securities and Exchange Commission ("SEC") on September 6, 2017, violates Sections 14(a) and 20(a) of the Exchange Act because it provides materially incomplete and misleading information about the Company and the Merger Agreement, including information concerning the Companys financial projections and analysis, on which the Board relied to recommend the Merger Consideration as fair to PharMerica shareholders. Plaintiff is represented by Faruqi & Faruqi, LLP, a law firm with extensive experience in prosecuting class actions, and significant expertise in actions involving corporate fraud. If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from the date of this notice. If you wish to discuss this action, or have any questions concerning this notice or your rights or interests, please contact: